Featured at this years ESMO event
Additional efficacy results from RELATIVITY-047 evaluating the fixed-dose combination of relatlimab (Lag3) and nivolumab vs. Opdivo monotherapy in previously untreated metastatic or unresectable melanoma.
saidSamit Hirawat, M.D., executive vice president, chief medical officer, Global Drug Development, Bristol Myers Squibb. - "Our data at this year’s ESMO show thatOpdivoandOpdivo-based regimens, including combinations with our immune checkpoint inhibitorYervoyand our third distinct immune checkpoint inhibitor relatlimab, have the potential to help advance the standard of care in both metastatic and earlier stages of cancer.”
The anticipation of the above should be enough to kick the share price into gear next week.
my opinion only
CHECKPOINT INHIBITORS - What The?, page-10
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.015(4.92%) |
Mkt cap ! $464.8M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 32.5¢ | 30.0¢ | $1.168M | 3.702M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 148547 | 32.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.5¢ | 51809 | 2 |
View Market Depth
| Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |